ClinicalTrials.gg
Not yet recruitingNCT07942480Updated Nov 17, 2026

Intraoral Scanner Assessment of Maxillary Marginal Soft Tissue Volume Change After Non-Surgical Periodontal Therapy in Type 2 Diabetes

An observational study in Periodontitis (Stage 3) and Type 2 Diabetes Mellitus (DM), sponsored by Emrah Bilen. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Emrah Bilen · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
72
Ages
18 Years and older
Sex
All
01

Study summary

Gum treatment (non-surgical periodontal therapy, also called scaling and root planing) reduces swelling in the gums. As the swelling goes down, the gum tissue around the teeth can shrink. This change is hard to measure with routine dental examinations. This study uses a 3D intraoral scanner, which takes digital images of the mouth without X-rays, to measure how much the gum tissue of the upper jaw changes in volume after treatment.

The study also asks whether this change is different in people with type 2 diabetes compared with people without diabetes. Diabetes can slow healing and change the body's inflammatory response, but its effect on gum volume after periodontal treatment has not been measured in three dimensions before.

Adults with stage III periodontitis who attend the Periodontology clinic at Afyonkarahisar Health Sciences University, Faculty of Dentistry, are invited to take part. Participants receive their routine gum treatment, which is not changed because of the study. Their upper jaw is scanned with an intraoral scanner before treatment and again at the routine 3-month check-up. The two scans are overlaid on a computer, and the change in gum volume is calculated. Researchers then compare people with and without type 2 diabetes.

Diabetes status and HbA1c values are taken from existing health records. The study does not require extra blood tests, X-rays, or extra visits.

02

Conditions studied

  • Periodontitis (Stage 3)
  • Type 2 Diabetes Mellitus (DM)

Keywords

  • Intraoral Scanner
  • Gingival Volume
  • Non-Surgical Periodontal Therapy
  • Scaling and Root Planing
  • Three-Dimensional Imaging
  • Soft Tissue Volume
  • HbA1c
03

In context

Periodontitis

1,235 studies on the registry are indexed under Periodontitis; 298 are open to participants now.

This study's planned enrollment of 72 is below the median of 90 across 374 observational studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

This is the only study on the registry with Emrah Bilen as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults with generalized stage III periodontitis attending the Periodontology clinic of Afyonkarahisar Health Sciences University, Faculty of Dentistry, who need routine non-surgical periodontal therapy. Participants are classified by existing health records as having type 2 diabetes or being systemically healthy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults aged 18 years or older who provide written

  • Generalized stage III periodontitis (2017 World Workshop classification)
  • All maxillary teeth present (third molars excluded)
  • Tooth mobility of Miller grade 0 or 1
  • Type 2 diabetes group: type 2 diabetes mellitus diagnosis confirmed from existing health records
  • Non-diabetic group: systemically healthy, with an existing below 5.7%

Exclusion criteria

Exclusion Criteria:

  • Stage IV periodontitis
  • Any tooth with Miller mobility grade 2 or 3 in the study area
  • Current smoking or heavy past smoking (10 pack-years or more)
  • Periodontal treatment or antibiotic use within the previous 6 months
  • Pregnancy or lactation
  • Medication causing gingival enlargement (e.g., phenytoin, cyclosporine, calcium channel blockers) or therapy
  • Systemic disease other than diabetes that affects the periodontium
  • Extensive restorations, fixed prostheses, or implants in the maxillary teeth
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
72 participants (estimated)
Patient registry
No

Groups and cohorts

  • Type 2 Diabetes With Stage III Periodontitis

    Adults with type 2 diabetes mellitus (diagnosis confirmed from existing health records) and generalized stage III periodontitis who receive routine non-surgical periodontal therapy at the Periodontology clinic. The treatment is not altered for the study. The upper jaw is scanned with an intraoral scanner before treatment and at the routine 3-month check-up.

  • No Diabetes With Stage III Periodontitis

    Systemically healthy adults without diabetes (confirmed from existing health records) with generalized stage III periodontitis who receive routine non-surgical periodontal therapy at the Periodontology clinic. The treatment is not altered for the study. The upper jaw is scanned with an intraoral scanner before treatment and at the routine 3-month check-up.

06

What researchers measure

Primary outcomes

  1. Change in Buccal Marginal Gingival Soft Tissue Volume of the Maxilla

    Volume change (mm3) of the buccal marginal gingival tissue of the maxillary arch, measured on superimposed 3D intraoral scans. Scans are overlaid on the tooth crown surfaces and the volume between baseline and 3-month surfaces is calculated within a region of interest bounded coronally by the gingival margin and apically by the mucogingival junction.

    Time frame: Baseline (before treatment) to 3 months after non-surgical periodontal therapy

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

Of 85 non-industry observational studies under Periodontitis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 14 months is below that.

Counting every sponsor, half of 86 studies reached it within 13 months; a quarter within 7 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Oct 27, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07942480
Lead sponsor
Emrah Bilen
Responsible party
Emrah Bilen (Assistant Professor, Afyonkarahisar Health Sciences University) — Sponsor-investigator
First posted
Nov 17, 2026
Start date
Oct 27, 2026 (estimated)
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion